Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL
Cancer Res. 2011 71 (5): 1871-82

PMID: 21324925 · PMCID: PMC3221734 · DOI:10.1158/0008-5472.CAN-10-1872

MeSH Terms (22)

Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Breast Neoplasms Cells, Cultured Female Gene Expression Gene Expression Profiling Humans Immunoblotting Immunoprecipitation Lapatinib Middle Aged Oligonucleotide Array Sequence Analysis Protein Multimerization Quinazolines Receptor, ErbB-2 Signal Transduction Trastuzumab

Connections (2)

This publication is referenced by other Labnodes entities:

Links